In two phase 1 randomised trials in 54 healthy volunteers, topical TAR-0520 gel (brimonidine tartrate 0.5–1.5%) caused no irritation in 50 and barely perceptible erythema in four, with minimal systemic absorption and dose-dependent vasoconstriction lasting over 24 h.
RCTn = 54
Andres et al. TAR-0520, a new candidate in oncodermatology: Results of a phase 1 program in healthy volunteers